Results of the October 2016 Innovation Grants competition

We are pleased to announce the results of the most recent Innovation Grants competition to support unique and creative research ideas that will impact cancer. Below is a listing of newly awarded Canadian Cancer Society (CCS) Innovation Grants.

Out of a total of 248 grant applications, 29 Canadian Cancer Society Innovation Grants have been approved – a 12% success rate. We had anticipated funding 22 grants, however funding has been approved for this higher number (29). Funds committed to this competition have been made possible by the significant efforts of CCS donors and volunteers across the country and by funding partners. CCS and the Canadian Institutes of Health Research – Institute of Cancer Research have partnered to support 9 Innovation grants focused on high fatality cancer research.  In addition, CCS and Brain Canada have partnered to support 4 Innovation grants focused on brain cancer research in this competition. This partnership leverages donations made to CCS with matching funds from Brain Canada through the Canada Brain Research Fund, a public-private partnership established by the Government of Canada, enabling more brain cancer research to be funded.  These projects total almost $5.7 million in funding over the full term of these grants.

Summaries of awarded grants

Please note: 

  • Amounts listed below represent the total dollars awarded by grant year and may include funds for salaries, supplies, and/or equipment.
  • The start date for these grants is February 1, 2017.
  • Only the Principal Investigator is named in this listing. Co-Principal Investigators, Co-Applicants and/or Additional Authors may also be associated with these grants.


Note Carefully:

Although every effort has been made to ensure the accuracy of the listing below, this list does not constitute an "official" notification.

Successful applicants will be informed, in writing, with an official Notification of Award giving the details pertaining to their grant.

Applicant
Institution
Title
Award
Aldape, Kenneth
Princess Margaret Cancer Centre - UHN
Molecular characterization of transcriptional repressor capicua (CIC) in glioblastoma
*co-funded by Brain Canada with the financial support of Health Canada
2017/2018 :  $98,000
2018/2019 :  $98,000
Beauregard, Jean-Mathieu
Laval University
Upregulating expression of somatostatin receptors to enhance peptide receptor radionuclide therapy for neuroendocrine tumours
2017/2018 :  $45,570
2018/2019 :  $75,215
2019/2020 :  $75,215
Boudreau, Jeanette
Dalhousie University
Development of natural killer cell–based precision immunotherapy for pancreatic cancer
*co-funded with CIHR-ICR
2017/2018 :  $98,000
2018/2019 :  $98,000
Chan, Warren
University of Toronto
Increasing nanoparticle tumour delivery efficiency
2017/2018 :  $97,572
2018/2019 :  $97,776
Cunningham, Charles
Sunnybrook Research Institute
The feasibility of hyperpolarized 13C-Pyruvate MRI for monitoring patients with intracranial metastasis
*co-funded by Brain Canada with the financial support of Health Canada
2017/2018 :  $94,938
2018/2019 :  $89,057
2019/2020 :  $3,920
Delisle, Jean-Sebastien
Hôpital Maisonneuve- Rosemont
Resident memory T cells as a new tool for adoptive T-cell therapy
2017/2018 :  $72,520
2018/2019 :  $74,480
2019/2020 :  $49,000
Di Noia, Javier
Institut de recherches cliniques de Montréal
A novel enzyme capable of metabolizing anticancer deoxycytidine analogs
2017/2018 :  $66,856
2018/2019 :  $66,924
2019/2020 :  $62,220
Done, Susan
Ontario Cancer Institute/Princess Margaret Cancer Centre
Heterogeneity and immune response in breast cancer
*co-funded with CIHR-ICR
2017/2018 :  $98,000
2018/2019 :  $98,000
Geyer, Clarence
University of Saskatchewan
Using synthetic antibody parts to construct antibody-based imaging devices: anti-EGFR molecular targeted imaging probes for diagnosing and monitoring glioblastoma
*co-funded by Brain Canada with the financial support of Health Canada
2017/2018 :  $97,968
2018/2019 :  $98,000
Giguere, Vincent
McGill University
A nuclear mTOR/DNA-PK complex: interaction with chromatin and its impact on prostate cancer
2017/2018 :  $98,000
2018/2019 :  $98,000
Gray, Douglas
Ottawa Hospital Research Institute
A novel therapeutic target for metastatic lung cancer
*co-funded with CIHR-ICR
2017/2018 :  $70,070
2018/2019 :  $70,070
2019/2020 :  $55,860
Hakem, Razqallah
Princess Margaret Cancer Centre - UHN
Breast cancer associated with BRCA1 mutations: synthetic lethality and therapeutic implications
2017/2018 :  $97,608
2018/2019 :  $97,608
Hoang, Trang
Université de Montréal
Dual molecular functions of LMO2 as a master oncogene in T-cell acute lymphoblastic leukemia
2017/2018 :  $98,000
2018/2019 :  $98,000
Howell, Doris
Princess Margaret Cancer Centre - UHN
Adaptation, feasibility and acceptability study of the advanced symptom monitoring and management system (ASyMS) mobile health intervention to reduce chemotherapy toxicities in Canadian cancer patients
*co-funded with CIHR-ICR
2017/2018 :  $98,000
2018/2019 :  $98,000
Jiang, Xiaoyan
BC Cancer Agency (Vancouver)
Targeting PAK6, a new target gene of miR-185 in drug-insensitive leukemic stem cells
2017/2018 :  $98,000
2018/2019 :  $98,000
Kim, Philip
University of Toronto
Developing inhibitors against c-Myc
2017/2018 :  $96,723
2018/2019 :  $96,723
Kleinman, Claudia
Jewish General Hospital
Novel biophotonic tools for understanding breast cancer metastasis signalling
2017/2018 :  $98,000
2018/2019 :  $98,000
Minchinton, Andrew
BC Cancer Agency (Vancouver)
Delivery and efficacy of targeted monoclonal antibody therapies in cancer: opportunities for therapeutic gains
2017/2018 :  $97,978
2018/2019 :  $97,989
Pollak, Michael
Lady Davis Institute
Direct inhibition of mRNA translation for treatment of pancreatic cancer
*co-funded with CIHR-ICR
2017/2018 :  $96,040
2018/2019 :  $96,040
Ravi, Ananth
Sunnybrook Research Institute
MOLLI: magnetic occult lesion localization and imaging
2017/2018 :  $98,000
2018/2019 :  $49,000
2019/2020 :  $49,000
Reimand, Jüri
Ontario Institute for Cancer Research
Integrative discovery of ion channels as drug targets in glioblastoma
*co-funded by Brain Canada with the financial support of Health Canada
2017/2018 :  $98,000
2018/2019 :  $98,000
Ross, Colin
University of British Columbia
Preclinical therapeutic development of targeted cardioprotectants for use in cancer patients receiving anthracycline chemotherapy
2017/2018 :  $96,883
2018/2019 :  $91,473
Schmitzer, Andreea
Université de Montréal
New biguanides for mitochondrial accumulation and inhibition of cancer progression
*co-funded with CIHR-ICR
2017/2018 :  $98,000
2018/2019 :  $98,000
Sidhu, Sachdev
University of Toronto
Co-targeting sensitizing integrin receptors and oncogenic growth factor receptors in lung cancer with bispecific antibodies
*co-funded with CIHR-ICR
2017/2018 :  $98,000
2018/2019 :  $98,000
Smith, Matthew
Université de Montréal
Real-time surveillance of multiplexed, reversible cancer signalling markers in perturbed RAS networks
*co-funded with CIHR-ICR
2017/2018 :  $64,190
2018/2019 :  $60,711
2019/2020 :  $69,139
Steidl, Christian
BC Cancer Agency (Vancouver)
Deciphering the cellular crosstalk in the tumour microenvironment of classical Hodgkin lymphoma
2017/2018 :  $98,000
2018/2019 :  $98,000
Tai, Isabella
University of British Columbia
Targeting tumour initiating cells in hepatocellular carcinoma to identify novel approaches in patient management
*co-funded with CIHR-ICR
2017/2018 :  $98,000
2018/2019 :  $98,000
Tinmouth, Jill
Sunnybrook Research Institute
Can online physician ratings be used to provide meaningful and actionable patient feedback? A mixed methods feasibility study
2017/2018 :  $97,020
2018/2019 :  $91,875
Wan, Yonghong
McMaster University
Enhancement of adoptive cell therapy by oncolytic vaccines
2017/2018 :  $62,263
2018/2019 :  $62,262
2019/2020 :  $62,262

Last modified on: February 6, 2017